806 Participants Needed

Church-based Health Intervention for Cardiovascular Disease

(CHERISH Trial)

JL
KT
Overseen ByKatherine T Mills, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Tulane University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two methods to reduce heart disease risk in predominantly Black communities in New Orleans. One strategy involves group education sessions, while the other uses community health workers for personal coaching and support. The researchers aim to determine which approach more effectively improves heart health by following evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD. Suitable participants have three or more heart disease risk factors, such as smoking, being overweight, or having high blood pressure. Participants should be connected to participating churches and live in the New Orleans area. As an unphased trial, this study offers a unique opportunity to contribute to community health improvements and potentially benefit from personalized heart health strategies.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the treatments in this trial adhere to the 2019 ACC/AHA guidelines for preventing heart disease. These guidelines emphasize that a healthy lifestyle is the safest and most effective way to prevent heart problems.

The treatments involve education on healthy living and heart health management, such as proper nutrition and monitoring blood pressure. These methods are generally easy to follow and safe, as they prioritize lifestyle changes over medications. No major side effects have been reported from adhering to these guidelines.

In summary, the treatments in this trial focus on lifestyle changes and are safe for participants.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores new strategies for preventing cardiovascular disease within church communities. Unlike standard medical treatments that often involve medications or clinical settings, these interventions leverage community-based education and support. The group-based education strategy offers sessions that teach self-monitoring of blood pressure and connect participants with primary care physicians. Meanwhile, the community health worker-led approach provides personalized coaching, navigation through healthcare systems, and integrates nutrition and exercise programs within church settings. These community-focused methods aim to make heart health management more accessible and supportive, potentially leading to better adherence and outcomes.

What evidence suggests that this trial's treatments could be effective for cardiovascular disease?

This trial will compare two strategies for preventing cardiovascular disease. Research has shown that community programs, such as the group-based education sessions in this trial, can enhance knowledge about heart disease and promote healthier habits, like improved diet and increased exercise. These programs have increased physical activity and reduced heart disease risk factors over time.

Another strategy in this trial involves implementation led by community health workers (CHWs). Studies indicate that CHWs can significantly reduce heart disease risk and encourage healthy behaviors. By providing personalized support and advice, CHWs have effectively helped individuals manage their heart disease risk. Both methods in this trial aim to reduce health disparities and improve heart health in communities, particularly among Black adults who face a higher risk.678910

Are You a Good Fit for This Trial?

The CHERISH study is for Black or African American adults aged 40 and over who are connected to participating churches in New Orleans. They must have at least four of these risk factors: smoking, obesity, low physical activity, poor diet, high cholesterol, high blood pressure, or elevated blood sugar. Those with recent severe health issues like cancer treatment or heart failure aren't eligible.

Inclusion Criteria

Criterion: People from the participating churches and their families and friends.
You have four or more of these health risk factors: smoking, being overweight, not getting enough exercise, not eating a healthy diet, high cholesterol, high blood pressure, or high blood sugar.
I am a Black or African American person aged 40 or older.
See 1 more

Exclusion Criteria

I haven't been hospitalized for heart failure or a heart attack in the last 3 months.
I do not have advanced kidney disease requiring dialysis or a transplant.
I do not need chemotherapy or radiation for any cancer right now.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Implementation

Participants receive a CHW-led multifaceted intervention or a group-based education strategy to address CVD risk factors

18 months
Regular visits at 6, 12, and 18 months

Follow-up

Participants are monitored for sustainability of the intervention and maintenance of cardiovascular health metrics

6 months post-intervention
1 visit (in-person) at 24 months

What Are the Treatments Tested in This Trial?

Interventions

  • Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Trial Overview This trial tests two strategies to improve cardiovascular health in the Black community using guidelines from the ACC/AHA. One strategy involves a community health worker leading various interventions; the other uses group education. The study will last 18 months and measure how well each method works.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Group-based Education StrategyExperimental Treatment1 Intervention
Group II: Community health worker-led implementation strategy:Experimental Treatment1 Intervention

Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD is already approved in United States for the following indications:

🇺🇸
Approved in United States as 2019 ACC/AHA Guideline on the Primary Prevention of CVD interventions for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Tulane University

Lead Sponsor

Trials
129
Recruited
259,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

Published Research Related to This Trial

A systematic review of 81 studies involving 17,275 participants found that church-based interventions significantly reduce cardiovascular disease (CVD) risk factors, including body weight, waist circumference, and systolic blood pressure.
The most effective interventions focused on increasing physical activity and improving diet, often incorporating cultural tailoring and spiritual components, which can help address health disparities in high-risk populations.
Systematic review and meta-analysis of church-based interventions to improve cardiovascular disease risk factors.Maroney, K., Laurent, J., Alvarado, F., et al.[2023]
This study involved 221 mid-life and older African Americans and aimed to reduce cardiovascular disease (CVD) risk through a church-based health intervention, highlighting the importance of community engagement in health programs.
The research found that while treatment and comparison groups had similar background characteristics and health behaviors, they differed in certain clinical factors, suggesting that targeted interventions may be necessary to address specific health disparities.
Reducing cardiovascular disease risk in mid-life and older African Americans: a church-based longitudinal intervention project at baseline.Ralston, PA., Lemacks, JL., Wickrama, KK., et al.[2022]
The study analyzed 833 patients and found that the ACC/AHA guidelines recommend statin treatment for nearly half (49.5%) of the participants, significantly more than the ESC guidelines, which suggest treatment for only 23.1%.
The ACC/AHA guidelines indicate a higher recommendation for statin use in men (62.6%) compared to women (40.4%), while the ESC guidelines show much lower recommendations for both genders (12% for women and 38.4% for men), highlighting a substantial difference in primary prevention strategies between the two guidelines.
Comparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohort.Yılmaz, M., Atar, İ., Hasırcı, S., et al.[2019]

Citations

Implementing and Evaluating Community Health Worker-Led ...Implementing and evaluating community health worker-led cardiovascular disease risk screening intervention in sub-Saharan Africa communities.
A community health worker led approach to cardiovascular ...The quantitative results showed significant reduction in participants' CVD risk after taking part in the interventions. We think these ...
A community health worker led approach to cardiovascular ...Effectiveness: quantitative results from intervention participants showed significant improvements in CVD behavioural risk factors across several measures.
Implementation of Evidence-Based Behavioral ...Extending cardiovascular disease prevention beyond health care settings is needed to improve population health and to advance health equity.
Evidence of Impact for Community Health WorkersA review by the CPSTF concluded that interventions that integrate CHWs on clinical care teams to prevent CVD are cost-effective.1,9 The median cost of ...
2019 ACC/AHA Guideline on the Primary Prevention of ...1. The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life.
2019 ACC/AHA Guideline on the Primary Prevention of ...1. The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life.
8.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/30879339/
2019 ACC/AHA Guideline on the Primary Prevention of ...1. The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life.
9.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/30879355/
2019 ACC/AHA Guideline on the Primary Prevention of ...2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force
2019 CVD Primary Prevention GuidelineThis guideline includes newly generated recommendations for aspirin use, and tobacco use, in addition to recommendations related to team-based ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security